Savara, Inc. (SVRA)
4.72
-0.27
(-5.41%)
USD |
NASDAQ |
Nov 12, 16:00
4.87
+0.15
(+3.18%)
After-Hours: 07:10
Savara Enterprise Value : 870.84M for Nov. 12, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 12, 2026 | 870.84M |
| November 11, 2026 | 926.34M |
| November 10, 2026 | 911.95M |
| November 09, 2026 | 938.67M |
| November 06, 2026 | 893.45M |
| November 05, 2026 | 800.96M |
| November 04, 2026 | 858.51M |
| November 03, 2026 | 877.01M |
| November 02, 2026 | 872.90M |
| October 30, 2026 | 891.40M |
| October 29, 2026 | 918.12M |
| October 28, 2026 | 932.51M |
| October 27, 2026 | 899.62M |
| October 26, 2026 | 829.74M |
| October 23, 2026 | 768.08M |
| October 22, 2026 | 833.85M |
| October 21, 2026 | 860.57M |
| October 20, 2026 | 879.07M |
| October 19, 2026 | 852.35M |
| October 16, 2026 | 815.35M |
| October 15, 2026 | 874.96M |
| October 14, 2026 | 879.07M |
| October 13, 2026 | 883.18M |
| October 12, 2026 | 895.51M |
| October 09, 2026 | 911.95M |
| Date | Value |
|---|---|
| October 08, 2026 | 893.45M |
| October 07, 2026 | 903.73M |
| October 06, 2026 | 856.46M |
| October 05, 2026 | 883.18M |
| October 02, 2026 | 889.34M |
| October 01, 2026 | 937.64M |
| September 30, 2026 | 961.28M |
| September 29, 2026 | 900.80M |
| September 28, 2026 | 898.75M |
| September 25, 2026 | 884.37M |
| September 24, 2026 | 898.75M |
| September 23, 2026 | 884.37M |
| September 22, 2026 | 945.99M |
| September 21, 2026 | 976.80M |
| September 18, 2026 | 960.37M |
| September 17, 2026 | 970.64M |
| September 16, 2026 | 911.07M |
| September 15, 2026 | 937.77M |
| September 14, 2026 | 954.21M |
| September 11, 2026 | 945.99M |
| September 10, 2026 | 950.10M |
| September 09, 2026 | 969.61M |
| September 08, 2026 | 993.23M |
| September 04, 2026 | 960.37M |
| September 03, 2026 | 960.37M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| ACADIA Pharmaceuticals, Inc. | 2.230B |
| Alnylam Pharmaceuticals, Inc. | 20.38B |
| Anika Therapeutics, Inc. | 166.16M |
| Vericel Corp. | 2.853B |
| Biogen, Inc. | 43.52B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -42.99M |
| Total Expenses (Quarterly) | 42.99M |
| EPS Diluted (Quarterly) | -0.1691 |
| Earnings Yield | -12.90% |
| Normalized Earnings Yield | -12.92 |